NEW YORK (
CHANGE IN RATINGS
rated new Buy at Sterne Agee. $71 price target. Focus on accretive outcome of a stronger brand and cloud based network.
downgraded at Needham from Buy to Hold, Needham said. Valuation call, as the stock is up 24% year-to-date.
downgraded at Wunderlich from Hold to Sell, Wunderlich said. $23 price target. Company is facing increased competition, which could cut into near-term growth.
downgraded at Needham from Buy to Hold, Needham said. Valuation call, based on a $20 price target.
downgraded at Jefferies to Hold from Buy at Jefferies. $75 price target. Revised assessment of regulatory risk.
upgraded to buy at TheStreet Ratings.
downgraded at Ticonderoga from Buy to Neutral, Ticonderoga said. Valuation call.
rated new Underperform at Jefferies. $9 price target. Low organic growth.
upgraded at Citigroup to Buy from Neutral, Citigroup said. $65 price target. Inspection and metrology targets the sweet spot of escalating foundry capital intensity.
rated new Outperform at Baird. $34 price target. Company has substantial growth prospects.
rated new Buy at Goldman. $28 price target. Permian basin should drive near-term growth for the company.
AllScripts Healthcare Solutions
rated new Buy at Sterne Agee. $24 price target. Leading electronic health record vendor.
upgraded at Citigroup to Buy from Neutral, Citigroup said. $60 price target. High probability LRCX-NVLS merger goes through mid year.
rated new Hold at Jefferies. $41 price target. Will face challenges given it generates over 80% of sales in US and Europe.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call, based on a $48 price target.
( PDX) downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Valuation call. Stock trades at a premium to its peers and there are downside risks to underlying oil prices.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, as the stock is up 35% over the past three months. $46 price target.
downgraded at UBS to Neutral from Buy, UBS said. $45 price target. Lack of cost savings and difficult volume environment.
downgraded at Kaufman to Hold, Kaufman Bros. said. $35 price target. Stock is already pricing in a bottoming of the business.
downgraded at Global Hunter from Accumulate to Neutral, Global Hunter said. $36 price target. Company will be hurt by the mild winter.
upgraded at Needham from Hold to Buy, Needham said. $41 price target. Company can take advantage of a unique supply/demand situation in the disk drive industry.
Winthrop Realty Trust
upgraded to buy at TheStreet Ratings.
downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Estimates also cut, because of lower realized revenue.
rated new Outperform at Baird. $12 price target. Company is a market leader and leveraged to secular growth drivers.
STOCK COMMENTS / EPS CHANGES
estimates, target boosted at Sterne Agee. Shares of AAPL now seen reaching $540, according to Sterne Agee. Estimates also upped, as the company's guidance could prove to be less conservative than usual. Buy rating.
target raised at Jefferies to $43, Jefferies said. Estimates also raised on strong reseller survey. Buy rating.
target raised at Oppenheimer to $84, Oppenheimer said. Asfotase Alfa is significant addition to future growth. Outperform rating.
Bank of Hawaii
numbers increased at Credit Suisse. BOH estimates were raised through 2014, Credit Suisse said. Company can is post increased capital deployment and earning asset growth. Neutral rating and new $47 price target.
numbers upped at Auriga. CSCO estimates were boosted through 2013, Auriga USA said. Company should benefit from improving product cycles and better enterprise demand. Buy rating and new $24 price target.
target raised at Oppenheimer to $21, Oppenheimer said. Industrial margins are reset. Outperform rating.
estimates, target cut at Credit Suisse. HAL estimates were reduced through 2013, Credit Suisse said. Company is likely to see lower domestic land-based sales. Outperform rating and new $54 price target.
Halliburton numbers adjusted at UBS. Shares of HAL now seen reaching $48, according to UBS. Estimates increased on encouraging international margins guidance. Buy rating.
Kansas City Southern
estimates lowered at UBS through 2013, UBS said. Noisy Q4 came up just shy, but revenue guidance looks good. Neutral rating and $66 price target.
Kansas City Southern numbers raised at Sterne Agee. Shares of KSU now seen reaching $69, according to Sterne Agee. Estimates also increased, to match the company's new guidance. Neutral rating.
estimates, target raised at Goldman.Shares of PLCM now seen reaching $21, according to Goldman Sachs. Estimates also increased, given better sales visibility. Neutral rating.
Polycom numbers raised at Citigroup.Shares of PLCM now seen reaching $24, according to Citigroup. Estimates also increased on better than expected revenues and margins. Buy rating.
target raised at UBS to $62, according to UBS. In line quarter with improving credit. Neutral rating.
target raised at Jefferies to $66, Jefferies said. Raise to reflect new initiatives, FX and SFSF consolidation. Hold rating.
estimates raised at UBS through 2013, UBS said. Q4 exceeds subdued expectations, demand remains healthy. Buy rating and $115 price target.
VMware estimates raised at Citigroup through 2013, Citigroup said. Guidance better than feared. Maintain Sell rating and $80 price target.
VMware numbers raised at Jefferies. Shares of VMW now seen reaching $94, Jefferies said. Estimates also raised on strong 4Q11 billings. Hold rating.
numbers reduced at Credit Suisse. Shares of ZION now seen reaching $24, according to Credit Suisse. Estimates also cut, as the company is facing net interest margin pressure. Outperform rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.